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Abstract
Background: Genomic gains and losses are a result of genomic instability in many types of cancers. BRCA1- and
BRCA2-mutated breast cancers are associated with increased amounts of chromosomal aberrations, presumably due
their functions in genome repair. Some of these genomic aberrations may harbor genes whose absence or
overexpression may give rise to cellular growth advantage. So far, it has not been easy to identify the driver genes
underlying gains and losses. A powerful approach to identify these driver genes could be a cross-species
comparison of array comparative genomic hybridization (aCGH) data from cognate mouse and human tumors.
Orthologous regions of mouse and human tumors that are commonly gained or lost might represent essential
genomic regions selected for gain or loss during tumor development.
Methods: To identify genomic regions that are associated with BRCA1- and BRCA2-mutated breast cancers we
compared aCGH data from 130 mouse Brca1
Δ/Δ;p53
Δ/Δ, Brca2
Δ/Δ;p53
Δ/Δ and p53
Δ/Δ mammary tumor groups with
103 human BRCA1-mutated, BRCA2-mutated and non-hereditary breast cancers.
Results: Our genome-wide cross-species analysis yielded a complete collection of loci and genes that are
commonly gained or lost in mouse and human breast cancer. Principal common CNAs were the well known MYC-
associated gain and RB1/INTS6-associated loss that occurred in all mouse and human tumor groups, and the
AURKA-associated gain occurred in BRCA2-related tumors from both species. However, there were also important
differences between tumor profiles of both species, such as the prominent gain on chromosome 10 in mouse
Brca2
Δ/Δ;p53
Δ/Δ tumors and the PIK3CA associated 3q gain in human BRCA1-mutated tumors, which occurred in
tumors from one species but not in tumors from the other species. This disparity in recurrent aberrations in mouse
and human tumors might be due to differences in tumor cell type or genomic organization between both species.
Conclusions: The selection of the oncogenome during mouse and human breast tumor development is markedly
different, apart from the MYC gain and RB1-associated loss. These differences should be kept in mind when using
mouse models for preclinical studies.
Background
Western women have a 10-12% risk of developing breast
cancer, making this disease the most common malig-
nancy in females [1]. Approximately 5-10% of breast
cancer cases can be explained by a hereditary predispo-
sition. Between 25-40% of these cases involves the
inheritance of one defective copy of either the BRCA1
gene or the BRCA2 gene [2-5] which predisposes
women in these families to a ~50-80% lifetime risk of
developing breast cancer and to a lesser extent ovarian
cancer [1].
BRCA1 and BRCA2 proteins are implicated in DNA
double strand break (DSB) repair and loss of BRCA
function results in chromosomal instability, hence to
cancer predisposition [6-8]. Chromosomal instability can
be evaluated by array-based comparative genomic
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number alterations (CNAs) in sample (tumor) DNA
relative to normal (diploid) DNA [9]. Analysis of the
recurrent regions of chromosomal instability in BRCA1
or BRCA2 mutated breast tumors may point to loci
and/or genes involved in development and progression
of BRCA-associated hereditary breast cancer. To gain
insight into the specific effects of BRCA1 or BRCA2 loss
on genomic instability, we used aCGH profiles of geneti-
cally defined mouse models for BRCA1- and BRCA2-
associated breast cancer as biological data filters to mine
the human breast cancer genome [10,11]. In these
mouse models breast cancer is driven by combined loss
of p53 and BRCA1 or BRCA2. The mouse p53
Δ/Δ mam-
mary tumors are a mix of basal carcinomas and carcino-
sarcomas, whereas the mouse Brca1
Δ/Δ;p53
Δ/Δ and
Brca2
Δ/Δ;p53
Δ/Δ tumors are mainly basal-like. Human
BRCA2-mutated tumors resemble sporadic tumors in
that they do not skew towards any phenotype [12],
whereas, 90% of human BRCA1-mutated tumors have a
basal like phenotype [10,12,13]. Of note, tumors from
our mouse models do not give rise to ER-positive lumi-
nal tumors, which is the cell type of 70-80% of human
sporadic and BRCA2-mutated breast tumors [14,15]. It is
well known that human basal-like and luminal human
breast tumors have different aCGH profiles [16]; therefore,
the comparison of aCGH profiles of mouse Brca1
Δ/Δ;p53
Δ/Δ
carcinomas with basal-like human BRCA1-mutated tumors
m a yg i v er e s u l t sr e l e v a n tf o rb a s a l - l i k eb r e a s tt u m o r sa sw e l l
as for BRCA1-loss.
Syntenic regions that are found recurrently gained or
lost in both human and mouse have a greater probabil-
ity of being relevant for development of BRCA-asso-
ciated and/or sporadic breast cancer [17]. To analyze
syntenic genomic regions for overlapping CNAs, we
applied two statistical frameworks to BRCA1-deficient,
BRCA2-deficient and BRCA1/2-proficient control
mouse and human breast cancers: a total of six tumor
groups. First we used KC-SMART [18], which identifies
significantly recurrent gains and losses within each
tumor group. Next, we identified syntenic CNAs that
co-occurred in both the mouse and human BRCA1-
mutated, BRCA2-mutated and control tumor groups.
Our data indicate that amplification of the MYC locus
and loss of the RB/INTS6 locus occurs in all mouse
and human tumor groups, and that AURKA amplifica-
tion occurs in mouse and human BRCA2-mutated
tumors. We also applied comparative-KC-SMART
which identifies gains and losses that occur significantly
more often in one tumor group compared to another.
We used this method to find CNAs that occur more
often in BRCA1- or BRCA2-deficient breast tumors
compared to BRCA-proficient control tumors. Next, we
identified which of these CNAs occur both in mouse
BRCA1- or BRCA2-deficient mammary tumors and in
human BRCA1- or BRCA2-mutated tumors. Together,
our KC-SMART and comparative-KC-SMART analyses
highlight important genotypic similarities between
mouse and human cognate cancers. However, we also
find several genomic aberrations to be highly recurrent
in one species but not in the other.
Methods
Mouse tumors
We bred cohorts of K14Cre;Brca1
F/F;p53
F/F female mice
[10], K14Cre;Brca2
F/F;p53
F/F female mice[11], and
K14Cre;p53
F/F female mice[10]. Cre recombinase expres-
sion in these mice is restricted to cytokeratin-14 (K14)
expressing epithelial tissues, including mammary gland
epithelium. We isolated DNA from 35 Brca1
Δ/Δ;p53
Δ/Δ,
62 K14Cre;Brca2
Δ/Δ;p53
Δ/Δ and 33 p53
Δ/Δ mammary
tumors as well as (tumor-free) spleens from the same
animals. Tumor type was scored by histopathology and
by expression levels of vimentin and E-cadherin: both
histopathology procedures and expression array proce-
dures were previously described in [10]. All animal
experiments were approved by the local ethical review
committee.
Mouse tumor aCGH profiles were obtained using a
microarray containing 3080 unique mouse bacterial arti-
ficial chromosome (BAC) clones spotted in duplicate, as
described previously [19]. Hybridizations were done as
described in Chung et al., 2004 with minor modifica-
tions. In brief, we labeled 2 μgo ft u m o rD N Aw i t hC y 5
and 2 μg reference (spleen) DNA with Cy3 and vice
versa for the dye swap (Universal Linkage System, Krea-
tech Biotechnology, Cat# EA-006) according to the
manufacturer’s protocol. All hybridizations were per-
formed in a hybridization station (Tecan, Cat# Hs4800).
Data, including detailed hybridization protocols were
added to the public repository Array Express with acces-
sion numbers E-NCMF-34 and E-NCMF-35 [20]. The
intensity of the Cy5 (tumor) signal was calculated rela-
tive to the intensity of the Cy3 (reference) signal for
each spot on the array and this ratio was log2 trans-
formed. Data was normalized by shifting these ratios by
the median log2 ratio per sub array. Dye swap data (a
total of four spots per data point) were combined using
the Rosetta error model [21]. Each mouse tumor DNA
sample was isolated from fresh tumor tissues and hybri-
dized against a reference DNA (spleen) obtained from
the same animal to avoid picking up DNA copy number
variations between mice.
To compare aCGH profiles from mouse with human
BRCA1- and BRCA2-mutated tumors, we used two pre-
viously published aCGH datasets [22,23]. For the cross-
species comparison: we used 27 human BRCA1-mutated
and 28 BRCA2 related breast tumors for the KC-SMART
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different cell types in the comparative-KC-SMART analy-
sis. Pathology, tumor type, and BRCA1- and BRCA2-
mutations of human tumors are shown in Additional file
1. All experiments with human materials were approved
by the local ethics review committee.
KC-SMART and comparative-KC-SMART analysis
KC-SMART
(Kernel Convolution - a Statistical Method for Aberrant
Region detection) determines which CNAs are signifi-
cantly recurrent within a tumor group [18]. KC-SMART
generates a Kernel Smoothed Estimate (KSE) for gains
(KSEgains)a n dl o s s e s( K S E losses) separately across the
genome and across agroup of tumors. Briefly, at the
genomic midposition of each BAC probe, KC-SMART
places a Gaussian kernel with the height of the sum of
either the positive log2 values or the negative log2
values of all tumors within a tumor group. KSE curves
(one for gains and one for losses) are point estimates
determined by convolution of locally weighted kernel
functions such that the closer the genomic distance
between two probes the more they will contribute to
each others convoluted values. Significance cut-offs are
calculated for gains and losses separately using the
distribution of KSE peak heights from randomized data
(P < 0.05) as explained in [18].
Comparative-KC-SMART
detects CNAs that occur significantly more often in one
tumor group compared to another. The algorithm cre-
ates a KSE curve for each individual tumor by placing
Gaussian kernel functions with the height of the log2
value and at the genomic midposition of each probe
(without separating gains and losses, as done for KC-
SMART analysis). For each genomic position in the KSE
curve, the KSE values from one tumor group are com-
pared to the KSE values from another group by calculat-
ing a signal to noise ratio (SNR). We determined a
cutoff that defines significant SNR values by applying a
False Discovery Rate (FDR) of 0.05 on the SNR data and
randomized SNR data using 6000 class-label
permutations.
T h ew i d t ho fak e r n e la p p l i e dt oe a c hd a t ap o i n t
determines the sensitivity of smoothing and the size of
aberrations detected. To compare mouse and human
tumor groups we consistently used one kernel width for
all tumor profiles. We found that, when using a 20 Mb
kernel width, KC-SMART best smoothed noise while
detecting CNAs from aCGH profiles of both mouse and
human individual tumors. To identify the genomic loca-
tions of the peaks of a KSE curve, we calculated for
which position the KSE value was higher (for gains), or
lower (for losses), compared to the values of its neigh-
boring datapoints. While in many instances a peak may
be a local maximum or minimum within a larger gain
or loss, these local peaks are part of the data and might
harbor interesting genes that drive the larger gain or
loss. An R-package of the KC-SMART algorithm (which
includes the comparative-KC-SMART algorithm) is
included in Bioconductor [24].
Combining mouse and human aCGH datasets
We used the BioMart data-mining tool in Ensembl Build
52 to cross-reference two Ensembl datasets (NCBI Build
36 and NCBI Build 37). Because NCBI Build 36 was
used to map the mouse RP23-BAC clones, we mapped
the genomic positions of the mouse genes using this
older build. However, in order to use the most current
mouse-human orthologue information, we matched the
ENSMUS numbers of NCBI Build 37 with their genomic
positions as listed in NCBI Build 36. We obtained a list
of 19589 unique mouse-human homolog combinations.
In this list we found 16679 unique human genes and
17048 unique mouse genes (one human gene may have
more than one mouse homolog and vice versa). We
determined which genes from this list map to the signif-
icantly gained or lost regions as determined by KC-
SMART method or to the differentially gained or lost
r e g i o n sa sd e t e r m i n e db yt h ecomparative-KC-SMART
method for the human and mouse tumor groups sepa-
rately. Next, we queried for those genes whose homolo-
gues map to regions gained or lost in both the human
and the mouse tumor sets. The locations of these genes
in the mouse and human genome are plotted by
connecting lines to their syntenic regions. Genomic
locations of the overlapping syntenic regions were deter-
mined by taking the genomic position of the start of the
first gene and the end of the last gene.
Results
1: aCGH analysis of mouse mammary tumors
To investigate the impact of BRCA1 and BRCA2 defi-
ciency on chromosomal instability in breast epithelial cells,
we performed aCGH on mammary tumors derived from
our genetically engineered mouse (GEM) models for
BRCA1- and BRCA2-associated breast cancer [10,11].
Mammary tumors in these mice arose from epithelial-spe-
cific loss of p53 alone (n = 33), or in combination with
BRCA1 (n = 35) or BRCA2 (n = 62). Typical examples of
aCGH profiles from Brca1
Δ/Δ;p53
Δ/Δ , Brca2
Δ/Δ;p53
Δ/Δ and
p53
Δ/Δ tumors are shown in Figure 1a. All but one tumors
in the Brca1
Δ/Δ;p53
Δ/Δ tumor group were of basal cell
type, consisting of primarily high grade invasive ductal car-
cinoma not otherwise specified (IDC-nos; 91%), 3% carci-
nosarcomas and 6% adenomyoepitheliomas (previously
described in [10]). Likewise, 90% of the Brca2
Δ/Δ;p53
Δ/Δ
tumors are carcinomas and 9% are carcinosarcomas. In
contrast, the p53
Δ/Δ tumor group consisted of mixed cell
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Page 3 of 16Figure 1 aCGH profiles of mouse mammary tumors. aCGH profiles typical of (a) Brca1
Δ/Δ;p53
Δ/Δ, Brca2
Δ/Δ;p53
Δ/Δ and p53
Δ/Δ mammary tumors.
Each dot represents the averaged log2 ratio (y-axis) of a BAC clone plotted at its genomic position (x-axis). Red dots (gains) and green dots
(losses) represent datapoints with log2 ratios significantly different from 0 as determined by the Rosetta error model [21]; black dots represent
datapoints with log2 ratios not significantly different from 0. Blue vertical lines represent chromosome boundaries. (b) aCGH profiles from 35
Brca1
Δ/Δ;p53
Δ/Δ tumors (blue), 62 Brca2
Δ/Δ;p53
Δ/Δ tumors (orange) and 33 p53
Δ/Δ tumors (gray) were analyzed with KC-SMART using a kernel width
of 20 Mb, for gains and losses separately. Significant CNAs are depicted in the color matched bars on top (gains) and below (losses) the Kernel
Smoothed Estimate curves (KSEs) for each tumor group. (c) The mean percentage of BAC clones ± S.E.M. with absolute log2 ratio > 0.3 is
greater across the Brca1
Δ/Δ;p53
Δ/Δ tumors (blue) and Brca2
Δ/Δ;p53
Δ/Δ tumors (orange) tumors compared with the p53
Δ/Δ tumors. P-values are
determined by a two-tailed t-test with unequal variance. (d) Each individual tumor aCGH profile was smoothed using KC-SMART (kernel width:
20 Mb). For a range of thresholds, all gains exceeding a positive threshold and losses exceeding the same negative threshold were counted and
averaged over each tumor group. Curves are darkened at thresholds for which the average number of CNAs per tumor group is significantly
greater in the Brca1/2
Δ/Δ;p53
Δ/Δ tumors compared with the p53
Δ/Δ tumors, P < 0.05 determined by a two-tailed t-test with unequal variance.
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nosarcomas and 11% adenomyoepitheliomas. Tumor type
scoring was based on histopathology and E-cadherin/
Vimentin expression, Table 1, (for tumor type data see
Additional files 2 and 3).
We used the KC-SMART method [18] to identify sig-
nificantly recurrent genomic aberrations in the aCGH
data of the mouse mammary tumor groups. Figure 1b
shows Kernel Smoothed Estimate curves (KSE curves;
see Methods) for gains and losses separately for the
Brca1
Δ/Δ;p53
Δ/Δ, Brca2
Δ/Δ;p53 and p53
Δ/Δ tumor groups.
Aberrations that exceeded the significance thresholds
are indicated by color-matched bars above (gains) or
below (losses) the KSE curves, and their genomic posi-
tions are listed in Additional file 4. Significantly recur-
rent gains (chromosomes 5, 6, 9-cen, 11-tel and 15) and
losses (chromosomes 4, 7-tel, 8, 10-tel, 12, 14, and 18)
overlapped between all tumor groups. Regional gains on
chromosomes 1, 2, 10, 17, 19 and losses on chromo-
somes 3, 13, 16 and X were common to both Brca1
Δ/Δ;
Trp53
Δ/Δ and Brca2
Δ/Δ;Trp53
Δ/Δ tumors but not to
Trp53
Δ/Δ tumors. In addition, a high level amplicon on
chromosome 10 occurred in >50% of the Brca2
Δ/Δ;
Trp53
Δ/Δ tumors.
Compared with the Brca1
Δ/Δ;Trp53
Δ/Δ tumor group,
the Trp53
Δ/Δ tumor group showed more whole chromo-
some gains and losses, rather than regional aberrations.
The Brca2
Δ/Δ;Trp53
Δ/Δ tumor group appeared to be an
intermediate version of both extremes. To quantify the
level of genomic instability for each tumor group we
calculated the mean percentage of BAC clones with log2
ratio >0.3 for gains and <-0.3 for losses separately and
found that this percentage was significantly higher for
the Brca1
Δ/Δ;p53
Δ/Δ and Brca2
Δ/Δ;p53
Δ/Δ groups com-
pared with the p53
Δ/Δ group (Figure 1c). Also the
Brca1
Δ/Δ;p53
Δ/Δ group had significantly more losses
than the Brca2
Δ/Δ;p53
Δ/Δ group.
Next, to quantify the amount of CNAs in each indivi-
dual tumor we smoothed their individual aCGH profiles
with KC-SMART (without separating gains and losses)
and determined the mean number of peaks in the KSE
curves exceeding a range of KSE thresholds. We found
that the average number of CNAs was significantly
higher in the Brca1
Δ/Δ;p53
Δ/Δ tumor group compared
with the p53
Δ/Δ tumor group between thresholds of 0.04
- 0.54, and significantly higher in the Brca2
Δ/Δ;p53
Δ/Δ
tumor group compared with the p53
Δ/Δ tumor group
between thresholds of 0.06 - 0.62 (Figure 1d). To exem-
plify the regions counted, we depicted the regions
exceeding an arbitrary threshold of 0.15 in line-plots
(Figure 2). Overall, gains and losses that occurred in the
p53
Δ/Δ tumor group also occurred in the Brca1
Δ/Δ;p53
Δ/Δ
and Brca2
Δ/Δ;p53
Δ/Δ tumor groups but in a greater frac-
tion of tumors, and with higher log2 ratios. Hence, Brca1
or Brca2 loss on top of p53 loss appears to aggravate the
tumor profile.
After stratifying the p53
Δ/Δ tumors according to tumor
type, we found that the carcinomas and adenomyoepithe-
liomas have significantly more genomic instability com-
pared with sarcomas (Figure 3). This could explain why
the KSE curves from the p53
Δ/Δ tumor groups (which
contain both carcinosarcomas and carcinomas) remain at
lower level compared with the KSE curves from the
Brca1
Δ/Δ;p53
Δ/Δ tumor and the Brca1
Δ/Δ;p53
Δ/Δ
tumor groups which contains mainly carcinomas
(Figure 1b).
aCGH analysis of human breast tumors
We compared aCGH data from our Brca1
Δ/Δ;p53
Δ/Δ,
Brca2
Δ/Δ;p53
Δ/Δ and p53
Δ/Δ tumor groups with aCGH
data from previously published BRCA1-mutated,
BRCA2-mutated and control human breast cancers
[22,23]. First, we assessed the genomic instability of the
human tumors by calculating the mean percentage of
BAC clones with log2 ratio >0.2 for gains and <-0.2 for
losses separately. The mean log2-ratio of the gains and
the losses in the aCGH data of human tumors was
lower compared to the mouse aCGH data (data not
shown); hence, a lower cutoff was used to calculate the
percentage of BACs reporting gains or losses in the
human CNAs. This percentage was significantly higher
for the gains of the BRCA1-mutated tumor group but
not for the BRCA2-mutated tumor group when com-
pared to the sporadic control tumors (p = 2.5 × 10
-3 cal-
culated with t-test with unequal variance) (Figure 4a).
The fraction of losses in the BRCA1 and BRCA2 tumor
groups were not significantly different from The fraction
of losses found in the sporadic control group. Next, to
get an indication of the amount of CNAs in each tumor
group, we smoothed the individual aCGH profiles with
KC-SMART and determined the mean number of gains
and losses in the KSE curves exceeding a range of
Table 1 Tumor types according to histopathology
mouse tumor group total scored Carcinoma Carcinosarcoma Adenomyoepithelioma NA
Brca1
Δ/Δ;p53
Δ/Δ (n = 35) 34 91% (31) 3% (1) 6% (2) 1
Brca2
Δ/Δ;p53
Δ/Δ (n = 62) 54 90% (49) 9% (5) 0% (0) 8
p53
Δ/Δ (n = 33) 28 39% (11) 50% (14) 11% (3) 5
Histopathology of Brca1
Δ/Δ;p53
Δ/Δ , Brca2
Δ/Δ;p53
Δ/Δ , p53
Δ/Δ mammary tumors, determined by H&E and/or vimentin, SMA, as previously described in [10].
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nificantly more CNAs compared with the sporadic con-
trol tumor group between thresholds of 0.08 - 0.24. The
average amount of gains and losses in the BRCA2-
mutated tumor group was not significantly increased
compared with the control group except between
thresholds of 0.06 and 0.08 (Figure 4b).
Cross-species comparison of mouse and human breast
tumors
Using aCGH data from genetically defined mouse mam-
mary tumors as a data filter to mine the human breast
cancer genome may be a powerful strategy to identify
genomic regions with functional relevance for breast
tumorigenesis [17]. To identify and narrow down
regions with highest relevance for BRCA related tumor
formation, we compared the array-CGH profiles of
human BRCA-mutated and sporadic breast tumors with
profiles from mouse BRCA-deficient and -proficient
mammary tumors. First, we performed a cross species
analysis using KC-SMART [18], which identifies signifi-
cantly recurrent CNAs within each tumor group.
Second, we adapted KC-SMART to comparative-KC-
SMART which identifies CNAs that occur with signifi-
cantly different frequency in one tumor group compared
to another (see Methods). Next, we performed cross
species analysis using comparative-KC-SMART, which
identified regions that occurred in BRCA-mutated
Figure 2 Gains and losses of individual mouse tumors. To visualize gains and losses of each individual mouse tumor we smoothed their
individual CGH profiles with KC-SMART (without separating gains and losses) and depicted the regions which exceeded an arbitrary threshold of
0.15 in line-plots. For those tumors for which the tumor type was known, we stratified according to tumor type. For each tumor depicted in
each line, the tumor type information is given in Additional file 3.
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versa) in both human and mouse breast tumors.
The following paragraphs describe the identification of
cross-species syntenic gains and losses. However, they
also show the challenges of interpreting cross-species
genomic data.
Cross-species analysis using KC-SMART
We used the KC-SMART method [18] to identify signif-
icantly recurrent CNAs in mouse and human breast
tumors and compared them between the two species
(Figure 5). Regions of significant gain or loss determined
by KC-SMART are shown in Additional file 4 for
mouse tumors and in Additonal file 5 for human
tumors. For comparison of mouse and human CNAs,
we used a synteny list of human genes and their mouse
orthologues (see Methods for details). Overlapping
CNAs in our cross-species comparison, and the cancer-
related genes that map within these regions are listed in
Figure 6 (single overlapping genes were left out, for
complete list see Additional file 6). We identified
human and mouse KSE peak locations and depicted the
closest cancer-related genes in Figure 6.
We identified one overlapping gain recurrent in all six
tumor groups on human chromosome 8q (mouse chro-
mosome 15). In all mouse tumor groups, the peak of
this gain was located at (for Brca2
Δ/Δ;p53
Δ/Δ and p53
Δ/Δ
tumors) or near (for Brca1
Δ/Δ;p53
Δ/Δ tumors) the region
containing the MYC oncogene at 128.8 Mb. The peak of
the human BRCA2-mutated tumors mapped exactly on
the MYC oncogene, and the peak of the human control
tumor group maps slightly downstream of MYC
(ADCY8, 132.21 Mb). All human tumor groups had a
second peak on chromosome 8 mapping between EXT1/
TNFRSF11B at 119.4 Mb and ENPP2/COL14A1, 120.87
Mb). This second peak was not shared with the mouse
tumor groups.
In all tumor groups, we found a recurrent region of
loss on chromosome 13q (mouse chromosome 14)
Figure 3 Genomic instability of mouse p53
Δ/Δ mammary
tumors: carcinomas and sarcomas. The 33 p53
Δ/Δ tumors
consisted of 14 sarcomas, 14 carcinomas/adenomyoepitheliomas
and the tumor type of 5 tumors was unknown. To find the
difference of genomic instability between carcinomas and sarcomas
we smoothed each individual tumor CGH profile using KC-SMART
(kernel width: 20 Mb). For a range of thresholds, gains exceeding a
positive threshold and losses exceeding the same negative
threshold were added and averaged over each tumor group.
Between KSE cutoffs of 0.14 and 0.4, the amount of CNAs is
significantly different between carcinomas and sarcomas, calculated
with a two sided t-test, P < 0.05, and shown by a gray background.
Figure 4 Genomic instability of human BRCA1-mutated, BRCA2-mutated and sporadic control breast tumors. (a) The mean percentage
of BAC clones ± S.E.M. with absolute log2 ratio >0.2 is greater in across the 27 BRCA1-mutated tumors (blue) and 28 BRCA2-mutated tumors
(orange) compared with 48 sporadic control tumors. P-values are determined by a two-tailed t-test with unequal variance. (b) Each individual
tumor aCGH profile was smoothed using KC-SMART (kernel width: 20 Mb). For a range of thresholds, all gains exceeding a positive threshold
and losses exceeding the same negative threshold were counted and averaged over each tumor group. Curves are darkened at thresholds for
which the average number of CNAs per tumor group is significantly greater in the BRCA1/2-mutated tumors compared with the sporadic control
tumors calculated with a two sided t-test with unequal variance, P < 0.05.
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Indeed, the overlapping regions of the mouse and
human BRCA2 groups include RB1.T h eo v e r l a po f
BRCA1 and control tumors mapped to the flanks of
these peaks, notwithstanding that loss of RB1 could well
drive the loss of this region in tumors of both species.
Interestingly, the overlap of all three tumor groups
included the region containing INTS6, an annotated
tumor related gene (also known as DICE1,P r o t e i n
deleted in cancer 1).
A remarkable similarity between mouse and human
BRCA2-mutated breast tumors was that the peak of both
the human (chromosome 20) and mouse (chromosome
2) centered exactly on the Aurora kinase A (AURKA)
oncogene. Similarly, the human control tumors showed
recurrent losses on chromosomes 16q and 17p, and the
peaks of syntenic losses in mouse p53
Δ/Δ tumors centered
on exactly the same genes on chromosomes 8 (MMP2)
and 11 (MAP2K4), respectively. This suggests that these
genes (or neighboring genes) may be involved in selec-
tion of these CNAs during mouse and human tumor
development. Note, however, that the Aurka gain also
occurred in mouse Brca1
Δ/Δ;p53
Δ/Δ tumors and that loss
of mouse chromosomes 8 and 11 was not specific for the
Brca1
Δ/Δ;p53
Δ/Δ tumors, suggesting that BRCA2 associa-
tion of the syntenic gain and BRCA1 association of the
syntenic losses are dictated by the human tumor data.
Large regions of chromosome 1 were recurrently
gained in the Brca1
Δ/Δ;p53
Δ/Δ tumors whereas shorter
regions were gained in the Brca2
Δ/Δ;p53
Δ/Δ tumors (see
Figure 2). Due to this difference in the mouse tumors,
there was a BRCA1-specific overlap with human chro-
mosome 1, as all other human tumor groups showed
this significantly recurrent gain. It is interesting that the
region of overlap encompasses PIK3CB and MDM4.
In the BRCA1 and BRCA2 tumor groups of both spe-
cies, we identified a recurrent loss on human chromo-
some 14 (mouse chromosome 12), peaking on ARID4A
(57.87 Mb) and DACT1 (58.17 Mb). All mouse tumors,
including the p53
Δ/Δ group, show this loss, encompass-
ing entire chromosome 12. Whether the region contain-
ing ARID4A and DACT1 contains a driver gene for this
whole chromosome loss remains to be established.
Cross species analysis using comparative-KC-SMART
To identify the CNAs that occur significantly more
often in mouse BRCA1-deficient tumors compared to
control tumors, we compared aCGH data from the
mouse Brca1
Δ/Δ;p53
Δ/Δ tumors with aCGH data from
Figure 5 Cross species KC-SMART analyses: overlapping recurrent CNAs of human and mouse breast tumors. We analyzed aCGH data
from mouse and human tumor groups with the KC-SMART algorithm using a kernel width of 20 Mb. Kernel Smoothed Estimate (KSE) curves are
shown for gains and losses separately. For each human-mouse comparison, the upper section shows the KSE curve of the mouse tumor group
(Mm) and the lower section shows the human tumor group (Hs). Regions that are gained or lost significantly more often compared to random
are depicted in red above or below the KSE curves. Genes that map to a syntenic region of significant gain or loss are plotted in red on the KSE
curves and are connected with gray lines between the species. The KSEs of the aCGH data were scaled such that the significance threshold
determined by KC-SMART analysis was set at 1 for gains and at -1 for losses. (a) Top panel: the gains on the mouse Brca1
Δ/Δ;p53
Δ/Δ tumor group
linked to the gains of the human BRCA1 tumor group (bottom panel). (b) Top panel: the losses on the mouse Brca1
Δ/Δ;p53
Δ/Δ tumor group
linked to the losses of the human BRCA1 tumor group (bottom panel). (c,d) Idem: mouse Brca2
Δ/Δ;p53
Δ/Δ and human BRCA2 tumor groups (e,f)
Idem: mouse p53
Δ/Δ and the human control tumor groups. The genomic locations of MYC, RB1, AURKA and ERBB2 genes are shown. Cancer
related genes that map in the overlapping regions are shown in Figure 6 (reduced list) and Additional file 6 (complete list).
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Page 8 of 16Figure 6 Genes in overlapping recurrent CNAs of human and mouse breast tumor determined by cross species KC-SMART analyses.
Overview of genes in regions found by cross species KC-SMART analysis (Figure 5): listed are genes that map to significantly recurrent regions of
gain and loss that overlap between (a) human BRCA1-mutated breast tumors and mouse Brca1
Δ/Δ;p53
Δ/Δ mammary tumors, (b) human BRCA2-
mutated breast tumors and mouse Brca2
Δ/Δ;p53
Δ/Δ mammary tumors, (c) human control breast tumors and mouse p53
Δ/Δ mammary tumors. The
syntenic genomic regions on the human and the mouse genome are listed as well as the amount of mouse genes (M) and human genes (H)
mapping within one region of overlap and the amount of unique orthologies for each pair of mouse and human genes (pair). The strand
inversion between the two species (when more than one gene maps within the region): 1: no strand inversion, -1: strand inversion. Cancer
related genes that map to the regions according to the Atlas of Genetics and Cytogenetics in Oncology and Haematology [44,45], and the
Cancer Gene Census [46,47] are listed: annotated cancer genes and genes from the Cancer Gene Census are shown in bold type, putative
cancer related genes are shown in normal type. Cancer related genes that map closest to the human KSE peak are shown in blue, genes that
map closest to the mouse KSE peak are shown in red, and genes that map to the mouse AND human KSE peaks are shown in green.
Overlapping regions with only one orthologue are not shown, for a complete list, including genes removed and added see Additional file 6.
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Δ/Δ tumors using comparative-KC-SMART. Simi-
larly, to determine which CNAs occur significantly more
often in the human BRCA1-mutated breast tumors com-
pared to the control tumor group, we used comparative-
KC-SMART on aCGH data from human tumors. Differ-
entially occurring gains are depicted in Figure 7a and
the differential losses are depicted in 7b; top panels
represent mouse Brca1
Δ/Δ;p53
Δ/Δ tumors compared with
p53
Δ/Δ tumors and lower panels represent human
BRCA1-mutated tumors compared to the control tumor
group. We next determined which genomic regions are
differentially recurrent in both mouse and human
BRCA1-mutated tumors by mapping the orthologous
genes of our synteny list to the differentially aberrated
regions in both species. The mouse and human ortholo-
gues are connected by gray lines between the top panel
and the lower panel. We applied the same analysis to
the mouse and human BRCA2-mutated tumors (Figure
7c,d).
Regional CNAs that occur significantly more often in
the Brca1
Δ/Δ;p53
Δ/Δ or Brca2
Δ/Δ;p53
Δ/Δ mouse tumor
groups compared with the p53
Δ/Δ control tumors are
listed in Additional file 7. For the complementing
human data see Additional file 8. The regions of
human-mouse overlap determined by comparative-KC-
SMART are listed in Figure 8 (regions with single over-
lapping genes were left out, for complete list see Addi-
tional file 9). Between the human and mouse, control
tumors show no syntenic regions of overlap in any of
the comparisons, therefore, the orthologous genes map-
ping to these regions are not connected. Regarding
regions encompassing more than one gene, there are 26
regions that overlap between mouse and human
BRCA1-mutated tumors (10 overlapping BRCA1-specific
gains and 16 losses), compared to only 4 overlapping
BRCA2-specific losses. This marked difference is due to
the lack of differential gains and losses between the
human BRCA2 tumors and sporadic control tumors.
The largest overlapping BRCA1-specific gain between
mouse and human BRCA1-mutated breast tumors maps
to human chromosome 1 and to mouse chromosome 6.
This region harbors the GADD45A gene, shown to be
induced by BRCA1 independently of p53 [25], and
implicated in regulating centrosome duplication and
maintaining genome integrity [26]. We speculate that
the GADD45A gene cannot be induced in BRCA1-defi-
cient cells, and that the necessity for its activity during
cellular division could select for its expression by
amplification.
The gain on human chromosome 7 maps to mouse
chromosome 6. This is one of the few gains in the
human tumors that are seen in the BRCA1-mutated
tumors but not in the control tumors. Similarly, the
gain in the centromeric region of mouse chromosome 6
is also not seen in the p53
Δ/Δ tumors, suggesting that in
this setting, this gain is BRCA1-specific in tumors of
both species. The mouse tumors have a peak on the
EXOC4 gene (alias SEC8, at 132.9 Mb), and the human
peak at the CALD1 gene (Caldesmon 1, at 134.2 Mb).
SEC8 is involved in cell-cell adhesion and is essential
for the development of epithel i a lc e l ls u r f a c ep o l a r i t y .
Caldesmon is a potential actomyosin regulatory protein
found in smooth muscle and nonmuscle cells. Whether
amplification of these genes selects for tumor develop-
ment remains speculation. There are several interesting
cancer-mutated genes in this region such as SMO
(smoothened, at 128.63 Mb) which was previously asso-
ciated with basal-like carcinomas [27] and the BRAF
oncogene (140.17 Mb) which regulates proliferation dif-
ferentiation, senescence and apoptosis through the RAS/
ERK pathway. Since these two genes roughly mark the
edges of the common amplicon it remains unclear
whether these genes are involved in driving the develop-
ment of this gain.
The overlapping gain on the telomeric end human
chromosome 12p maps to the telomeric part of mouse
chromosome 6. The mouse tumors have a small peak
on CLEC12A, but the actual peak of the amplicon is at
the end of chromosome 6, which encompasses the
oncogenic Kras gene; however, this region is not part of
the human-mouse overlap. The human tumors have a
peak on STRAP (alias MAWD,a t1 5 . 9 3M b )w h i c hh a s
previously been shown to be overexpressed in breast
cancer [28]. The driving gene(s) of this overlapping gain
might therefore differ between mouse and human breast
tumors.
Loss of human chromosome 5q is strongly associated
with BRCA1-mutated tumors [29]. This region might
therefore contain tumor suppressor gene(s) that collabo-
rate with BRCA1-loss in tumorigenesis. The first part of
human chromosome 5q maps to the telomeric half of
mouse chromosome 13, which is not lost significantly
more often in the mouse Brca1
Δ/Δ;p53
Δ/Δ tumors com-
pared to the p53
Δ/Δ tumors, with the exception of the
telomeric region. The human peak (which is only a
small peak adjacent to a more intense peak) and the
mouse peak localize at the region encompassing the
MAP3K1 and PLK2 genes. There are two chromosome
5 syntenies mapping to consecutive regions on mouse
chromosome 18. The SPINK7 gene (also known as
ECRG2, esophageal cancer related gene 2) maps close to
the peak of both the mouse and human loss. Again, its
involvement in driving the chromosome 5 loss remains
to be established.
The BRCA1-specific loss on human chromosome 12
maps to mouse chromosome 10 and consists of three
separate losses. The first part peaks at the GLS2 gene,
whereas the mouse loss peaks at the ITGA7 gene. This
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(melanoma-associated antigen), CDK2, ERBB3, CDK4
and the DDIT3, but since these genes are part of the
mitogenic signaling pathways, it is unlikely that these
genes are drivers of this loss. The second loss on human
chromosome 12 is a peak region encompassing five
genes, of which one, KITLG, is listed as a putatively can-
cer related gene. The third loss on chromosome human
1 2a l s om a p st om o u s ec h r o m o s o m e1 0 .T h em o u s e
loss peaks on APAF1, involved in apoptosis, and the
human tumors show a peak at the end of the loss, just
outside the overlap.
The human BRCA2-mutated tumor group is very com-
parable to the control tumor group, and therefore shows
only one overlapping region with mouse Brca2
Δ/Δ;p53
Δ/Δ
tumors. The human chromosome 13 is one consecutive
loss previously associated with RB1,w h i c hm a p si n
different parts to mouse chromosome 14. Indeed, RB1
( 4 7 . 9 5M b )m a p st ot h i sl o s s ,c l o s et ot h ep e a k so fb o t h
mouse (TSC22D1 at 43.9 Mb) and human tumors
(OLFM4 at 52.5 Mb).
Discussion
During tumor development, acquired genetic aberrations
that confer selective advantage will become enriched in
the tumor cell population. To identify the drivers under-
lying the gains and losses selected for during breast can-
cer development, we made use of the synteny between
human and mouse genomes [30]. Syntenic gains and
losses that occur in both the mouse and human
Figure 7 Cross species comparative-KC-SMART analyses. (a) The upper section shows the KSE curves of the gains of the mouse Brca1
Δ/Δ;
p53
Δ/Δ (blue) and p53
Δ/Δ (gray) tumor groups. The positions of the genes that map in regions that are aberrated significantly more often in the
Brca1
Δ/Δ;p53
Δ/Δ compared to the p53
Δ/Δ group are depicted in red on the blue curve and shown as red bars on the bottom of the panel. Vice
versa, the positions of the genes that map in regions that are aberrated significantly more often in the p53
Δ/Δ compared to the Brca1
Δ/Δ;p53
Δ/Δ
group are depicted in green on the gray curve and shown as green bars on the bottom of the panel. Similarly, the lower section shows the KSE
curves of the gains of the mouse human BRCA1-mutated (blue) and sporadic (gray) tumor groups. Those genes that map to syntentic regions
that are differentially aberrated in tumors of both species are connected between the two plots by gray lines. Thicker connecting lines represent
multiple genes that map to one syntenic region of gain. (b) Idem: differential losses of the mouse Brca1
Δ/Δ;p53
Δ/Δ (blue) and p53
Δ/Δ tumor groups
(gray) and human BRCA1-mutated (blue) and sporadic tumors(gray) (lower section). (c,d) Idem: differential gains and losses of the mouse Brca2
Δ/
Δ;p53
Δ/Δ (blue) and p53
Δ/Δ tumor groups (gray) and human BRCA2-mutated (blue) and sporadic tumors(gray) (lower section). Gains: No genes
were differentially aberrated in tumors of both species. Cancer related genes that map in the overlapping regions are shown in Figure 8
(abbreviated list) and Additional file 9 (complete list).
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or genetic elements that are causal to tumor develop-
ment in both species. Indeed, comparative aCGH ana-
lyses showed that many genetic aberrations are
conserved between human and mouse neuroblastomas
[31,32], ovarian cancers [33], hepatocellular carcinomas
[34], melanomas [35] and T-cell lymphomas [36]. In this
work, we analyzed and compared aCGH data from a
large series of mouse and human BRCA1- and BRCA2-
mutated breast cancers, in order to obtain a complete
collection of genes and loci that are recurrently gained
or lost in tumors of both species. We find that
amplification of the MYC locus and the loss of the RB/
INTS6 locus is evolutionarily conserved in mouse and
human mammary tumor development, and that AURKA
amplification is conserved in mouse and human BRCA2-
mutated tumors. However, aside from these similarities,
we also find recurrent aberrations in mouse and human
oncogenomes that do not overlap.
Brca1 and Brca2 loss intensifies aCGH patterns of mouse
p53
Δ/Δ mammary tumors
Because mouse models enable targeted deletion of speci-
fic gene(s) in a defined genetic background it is possible
Figure 8 Genes in overlapping recurrent CNAs of human and mouse breast tumor determined by cross species comparative-KC-
SMART analyses. Overview of genes in regions found by cross species comparative-KC-SMART analysis (Figure 7). Listed are genes that map to
significantly differentially gains and losses that overlap (a) between mouse Brca1
Δ/Δ;p53
Δ/Δ mammary tumors (compared to p53
Δ/Δ tumors) and
human BRCA1-mutated breast tumors (compared to control tumors) and (b) between mouse Brca2
Δ/Δ;p53
Δ/Δ mammary tumors (compared to
p53
Δ/Δ tumors) and BRCA2-mutated breast tumors (compared to control tumors). Idem Figure 6. For complete list see Additional file 9.
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organism. With our mouse models, we analyzed the
impact of BRCA1 or BRCA2 loss on the oncogenome,
in a p53 deficient background. KC-SMART profiles of
mouse Brca1
Δ/Δ;p53
Δ/Δ and Brca2
Δ/Δ;p53
Δ/Δ mammary
tumors showed that significantly recurrent genomic
aberrations largely overlap with recurrent aberrations in
p53
Δ/Δ tumors and that these common aberrations
occur more frequently in Brca1
Δ/Δ;p53
Δ/Δ and Brca2
Δ/Δ;
p53
Δ/Δ mammary tumor compared to the p53
Δ/Δ tumor
group. This suggests that BRCA1 or BRCA2 loss intensi-
fies the profile of aberrations seen in the p53
Δ/Δ tumor
group.
We find that the p53
Δ/Δ tumors that are BRCA profi-
cient more often gain or lose entire chromosomes dur-
ing tumor development. In contrast, Brca1
Δ/Δ;p53
Δ/Δ
and Brca2
Δ/Δ;p53
Δ/Δ tumors have an increased amount
of partial chromosomal gains and losses, presumably
because they have accumulated more inter- and intra-
chromosomal DNA damage as a result of error-prone
DSB repair in the absence of homology directed DNA
repair. The inability of these cells to properly repair
DSBs might allow selection of gains and losses more
specifically tailored around the relevant genes in a
region. Interestingly, most gains and losses found in the
p53
Δ/Δ tumor group are intensified by Brca1 or Brca2
loss but some are not, such as the gain on chromosome
15 and the losses on chromosomes 7 and 12. These
regions may therefore be subject to a differential selec-
tion pressure during tumor development.
It appears that cell type also plays an important role:
the carcinomas of the p53
Δ/Δ tumor group seems to
have more genomic damage compared with the carcino-
sarcomas. This may be the reason that BRCA1 and
BRCA2 loss gives rise to a more aggravated DNA
damage profile, as >90% of Brca1
Δ/Δ;p53
Δ/Δ tumors and
Brca2
Δ/Δ;p53
Δ/Δ mammary tumors are carcinomas, com-
p a r e dt oh a l fo ft h ep53
Δ/Δ mammary tumors, of which
the other half are sarcomatoid. This suggests that in
these mouse models BRCA1 loss and BRCA2 loss blocks
cellular differentiation as suggested previously [37], or
alternatively, that BRCA1 and BRCA2 loss are not toler-
ated in more differentiated cells.
Differences between mouse Brca1 and Brca2 mutated
tumors
Despite their common p53 deficient background, some
aberrations may be more prone to arise in a BRCA1 defi-
cient cell, whereas others are more likely to occur in a
BRCA2 deficient cell. For example, the recurrent gain on
chromosome 1 or the losses on chromosomes 4 and 9 of
the Brca1
Δ/Δ;p53
Δ/Δ tumors are less common in the
Brca2
Δ/Δ;p53
Δ/Δ tumors. Likewise, the prominent gain on
c h r o m o s o m e1 0i sf o u n di nh a l fo fa l lBrca2
Δ/Δ;p53
Δ/Δ
tumors, and in approximately 1/8 of the Brca1
Δ/Δ;p53
Δ/Δ
tumors. In addition, it appears that in a p53 deficient
background, Brca1 loss gives rise to more genomic aber-
rations than does Brca2 loss. Together, these differences
in tumor profiles suggest that BRCA1 and BRCA2 have
different functions in DNA repair pathways, however, we
have not been able to identify the nature of this differ-
ence using our aCGH profiles.
Comparative oncogenomics identifies similarities and
differences in mouse and human breast tumors
Cross species comparison of genomic aberrations in
human and mouse tumors may identify conserved geno-
mic regions likely to be important for development in
both species. Tumors from genetically engineered
mouse models often do not show the high levels of
chromosome instability associated with human cancers
[36], presumably because the engineered mutations pre-
dispose to rapid tumor formation and thereby circum-
vent the long incubation time required for accumulation
of genomic mutations in human tumorigenesis. The
increased amounts of genomic alterations in tumors
from mice with engineered telomere dysfunction or
defects in DNA damage checkpoints or DNA repair
allows comparison of genomic alterations with human
tumors that would not be possible in mouse models
without chromosomal instability [36].
In our analysis, we compared aCGH profiles from
human BRCA1/2-mutated and sporadic breast cancers
with profiles from mouse p53
Δ/Δ, Brca1
Δ/Δ;p53
Δ/Δ and
Brca2
Δ/Δ;p53
Δ/Δ mammary tumors. We assume that
DNA damage repair deficiency in the mammary epithe-
lium of these mice allows a comparable selective advan-
tage in tumor formation as in human breast epithelial
cells. Indeed, all human tumor groups showed a recur-
rent gain on chromosome 8q, likewise all mouse tumor
groups showed a recurrent gain on its syntenic region,
on chromosome 15, centering exactly on the MYC
oncogene. This suggests that MYC gain is evolutionarily
conserved in mammary tumor development from mouse
to man. Likewise, the chromosome 13 loss, associated
with RB1 loss [38] occurs in all human and mouse
tumor groups, and all overlapping regions encompass
the INTS6 gene. Similar to MYC gain, RB1/INTS6 loss
could be evolutionarily conserved in mammary tumor
development.
The defined initiating lesions and similar genetic back-
ground of mouse mammary tumors permits identifica-
tion of recurrent genomic aberrations linked to certain
genetic predispositions. Indeed, the amplification peak
on human chromosome 20 overlapped with the syntenic
amplification peak on mouse chromosome 2 of the
Brca1
Δ/Δ;p53
Δ/Δ and the Brca2
Δ/Δ;p53
Δ/Δ tumors, at the
Aurora Kinase A gene. The AURKA gain has been
Holstege et al. BMC Cancer 2010, 10:455
http://www.biomedcentral.com/1471-2407/10/455
Page 13 of 16previously associated with BRCA2-mutated breast tumor
development [39] but our findings suggest that the func-
tional interaction between AURKA and BRCA2 may be
evolutionarily conserved. The mouse Brca1
Δ/Δ;p53
Δ/Δ
tumors also showed the gain on chromosome 2 but the
p53
Δ/Δ tumors, on the other hand, did not show this
gain at all, suggesting that this gain may selectively
develop in a homologous repair deficient (HRD)
background.
For most other overlapping gains and losses reported
in the results section, it is still difficult to associate a
driver gene with a gain or a loss. Also, gains known to
be important in human BRCA1-mutated breast cancer
show no (e.g. 3q gain) or only partial (e.g. the 5q loss)
overlap with the mouse gains and losses. The human 3q
gain is associated with PIK3CA overexpression; possibly,
mouse tumors may find alternative ways to overexpress
this gene or a functional homologue. Alternatively,
PIK3CA overexpression might not provide a selective
advantage in these mouse tumors, or mouse tumors in
general. The regions susceptible for amplification or
deletion in the mouse genome and the human genome
m a yn o tb et h es a m ed u et o ,f o re x a m p l e ,d i f f e r e n t
nuclear chromosomal folding or genomic organization
of synteny blocks, resulting in a differential development
of the oncogenome during mouse and human tumor
development. These findings add to previous findings of
differences between mouse and human breast cancer
development such as that activation of Wnt and/or its
pathway members are commonly found in mouse but
not in human spontaneous breast tumors, differences in
metastasis patterns, or that few mouse models accu-
rately represent ER positive human breast cancers [40].
Conclusions
In this work we have found some important genotypic
similarities between mouse and human cognate cancers,
such as the MYC gain and the RB/INTS6 loss, but also
important differences such as the chromosome 10 gain
in mouse Brca2
Δ/Δ;p53
Δ/Δ tumors and the 3q gain in
human BRCA1-mutated tumors. In our mouse models,
we find that BRCA1 and BRCA2 loss clearly have differ-
ent impacts on tumor development. However, the dis-
tinct features of mouse Brca1
Δ/Δ;p53
Δ/Δ and Brca2
Δ/Δ;
p53
Δ/Δ tumors did not translate to distinct features of
human BRCA1 and BRCA2 mutated tumors and vice
versa. A reason for this could be that tumor develop-
ment in our mouse models is a fast, accelerated version
of the relatively slow process of tumor development in
humans. Simultaneous and homozygous deletion of the
mouse Brca1, Brca2 and p53 genes leads to immediate
cellular transformation, whereas human germline
BRCA1 and BRCA2 mutations are initially heterozygous
[41,42]. Human TP53 mutations are somatic and can be
acquired in myriad different ways, possibly resulting in
different phenotypes [43]. In addition, the difference in
make-up of the mouse and human genome, such as the
genome wide organization of syntenic regions, and/or
overall differences between mouse and human mam-
mary gland biology may result in selection of other
regions and genes during the course of mouse and
human breast cancer development. These differences
should be taken into account when using K14cre;Brca1
F/
F;p53
F/F and K14cre;Brca2
F/F;p53
F/F mouse models for
preclinical studies.
Additional material
Additional file 1: Histopathology, BRCA1/BRCA2 mutations, tumor
types of human breast tumors. Immunohistochemistry: Presence of ER,
PR, ERBB2 (HER2/neu) and TP53 was determined by
immunohistochemistry staining using the antibodies: estrogen receptor
AB-14 clone 1D5 + 6F11, titre 1:50 (Neomarkers); progesterone receptor
clone PR-1 titre 1:400 (Immunologic), c-erbB-2 clone SP3, titre 1:25
(Neomarkers); TP53 clone D0-7, titre 1:8000 (Dako). If >70% of the tumor
cells expressed ER, PR, or TP53, the tumor was scored as positive (+) for
the corresponding staining, in case <10% of the cells were stained, the
tumor was scored as negative (-) and between 10 and 70% the tumor
was scored as ± for the corresponding staining. HER2/neu staining was
scored positive when a 3+ staining was observed (*), otherwise it was
scored negative (only one sporadic control case was IHC 2+, and was
called negative). *) Wolff AC, Hammond ME, Schwartz JN, Hagerty KL,
Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College
of American Pathologists guideline recommendations for human
epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol
2007 Jan 1;25(1):118-45.
Additional file 2: Tumor type characterization of mouse mammary
tumors by Vimentin and E-Cadherin expression analysis.T o
determine tumor type, log2 ratios of Vimentin and E-Cadherin expression
were acquired by hybridization of mRNA of a subset of tumors on
Mouse Operon V3 Oligo arrays and were plotted against each other. a)
Brca1
Δ/Δ;p53
Δ/Δ, Brca2
Δ/Δ;p53
Δ/Δ and p53
Δ/Δ mouse tumors were plotted by
their E-cadherin and Vimentin expression levels. b) If the difference
between E-cadherin and Vimentin expression levels was less than 0.5 on
a log scale these tumors were called ‘ambiguous’. Tumors were scored
‘Mesenchymal’ if the Vimentin expression level was >0.5 higher than E-
cadherin expression level. Likewise, tumors were scored ‘Epithelial’ when
the E-cadherin expression level was >0.5 higher than the Vimentin
expression.
Additional file 3: Tumor types of mouse mammary tumors
determined by histopathology and gene expression analysis. Mouse
mammary tumor types were determined by histopathology and
expression data. Histopathology was done as previously described in [10].
Expression data was acquired by hybridization of mRNA of a subset of
tumors on Mouse Operon V3 Oligo arrays: If the difference between E-
cadherin and Vimentin expression levels was less than 0.5 on a log scale
we called these tumors ‘ambiguous’. Tumors were scored ‘Mesenchymal’
if the Vimentin expression level was >0.5 higher than E-cadherin
expression level. Likewise, tumors were scored ‘Epithelial’ when the E-
cadherin expression level was >0.5 higher than the Vimentin expression
level. The line numbers relate to the line-plots shown in Figure 2, line
number 1 on top for each tumor group.
Additional file 4: KC-SMART analysis of mouse mammary tumors.
The significant CNAs of Brca1
Δ/Δ;p53
Δ/Δ, Brca2
Δ/Δ;p53
Δ/Δ and p53
Δ/Δ mouse
tumor groups were obtained by running the KC-SMART algorithm over
the BAC data from all tumors in each tumor group using a kernel width
of 20 Mb. Significant regions are determined by the intercept of the KSE
curve and the significance cutoff calculated for each tumor group, and
for gains and losses separately. The upper panel lists recurrent gains and
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the color-matched bars on top (gains) and on the bottom (losses) of the
KSE curves of the tumor groups shown in Figure 1d and the red bars of
the cross species comparison in Figure 5.
Additional file 5: KC-SMART analysis of human breast tumors.
Genomic regions found recurrently gained (top) or lost (bottom) by KC-
SMART analysis of human BRCA1-related, BRCA2-related, and control
breast tumors. The significant CNAs were determined by running the KC-
SMART algorithm over the BAC data from all tumors in each tumor
group using a kernel width of 20 Mb. Significant regions are determined
by the intercept of the KSE curve and the significance cutoff calculated
for each tumor group, and for gains and losses separately. The upper
panel lists recurrent gains and the bottom panel lists the recurrent losses.
Additional file 6: Regions identified by cross-species KC-SMART
analysis. Shown are genes within significantly recurrent regions of gain
and loss that overlap between (a) human BRCA1-mutated and mouse
Brca1
Δ/Δ;p53
Δ/Δ tumors, (b) human BRCA2-mutated and mouse Brca2
Δ/Δ;
p53
Δ/Δ tumors, and (c) human control tumors and mouse p53
Δ/Δ tumors
as shown in Figure 5. The syntenic regions in the human and the mouse
genome are listed in columns 1 and 2. The “Orthology” column lists the
number of mouse (M) and human (H) genes mapping within each
region of overlap, and the number of unique orthologous pairs (pair).
Strand inversion between the two species is indicated by 1 (no
inversion) or -1 (inversion). Listed are cancer-related genes included in
the Atlas of Genetics and Cytogenetics in Oncology and Haematology
[44,45], and the Cancer Gene Census (CGC)[47,46]. Annotated cancer
genes and CGC genes are shown in bold type, putative cancer genes are
shown in normal type. Cancer-related genes that map closest to the
human KSE peak are shown in blue and genes that map closest to the
mouse KSE peak are shown in red. Genes that map to the mouse AND
human KSE peaks are shown in green. Single genes that were not listed
in the Atlas or the CGC are shown in italics.
Additional file 7: Comparative-KC-SMART analysis of mouse
mammary tumors. The significant differential gains and losses of Brca1
Δ/
Δ;p53
Δ/Δ vs. p53
Δ/Δ and Brca2
Δ/Δ;p53
Δ/Δ vs. p53
Δ/Δ mouse tumor groups were
obtained by running the comparative-KC-SMART algorithm over the BAC
data from all tumors in each tumor group using a kernel width of 20
Mb. The upper panel shows recurrent differential gains and the bottom
panel shows the differential losses. These regions correspond to the red
bars plotted on top (gains) and on the bottom (losses) of the
corresponding mouse KSE curves used in the cross species comparison
in Figure 6.
Additional file 8: Comparative-KC-SMART analysis of human breast
tumors. Comparative KC-SMART analysis of human BRCA1-related and
BRCA2 related breast tumors compared with control breast tumors.
Regions of differential aberrations between BRCA1 and control breast
tumors, between BRCA2 and control breast tumors. Top panel:
Differential gains. Bottom panel: Differential losses.
Additional file 9: Regions identified by cross-species comparative-
KC-SMART analysis. Shown are (a) genes that map to differentially
recurrent CNAs found in both mouse Brca1
Δ/Δ;p53
Δ/Δ vs. p53
Δ/Δ mammary
tumors and human BRCA1-mutated vs. control breast tumors and (b)
genes mapping to differentially recurrent CNAs found in both mouse
Brca2
Δ/Δ;p53
Δ/Δ vs. p53
Δ/Δ mammary tumors and BRCA2-mutated vs.
control breast tumors, shown in Figure 7
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